However, under pathological conditions of NAFLD/NASH, the expression of FGF21 would be increased in liver, which may be due to the "FGF21 resistance" phenomenon caused by the body's desire to improve the disease state by increasing FGF21. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.